EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting Protein Kinase, Membrane-Associated Tyrosine/Threonine 1 (PKMYT1) for Precision Cancer Therapy: From Discovery to Clinical Trial

Ming Yang, Hua Xiang iD, Guoshun Luo iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c01619 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Ming Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198,…. Hauptthemen laut MEDLINE: Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 120 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

\Protein kinase membrane-associated tyrosine/threonine 1 (PKMYT1), an overlooked member of the WEE family responsible for regulating cell cycle transition, has recently emerged as a compelling therapeutic target for precision cancer therapy due to its established synthetic lethal relationship with CCNE1 (cyclin E1) amplification. Since the first-in-class selective PKMYT1 inhibitor, RP-6306, entered clinical trials in 2021, the field has experienced renewed interest underscored by the growing number of inhibitor patents and the exploration of additional gene alterations, such as KRAS/p53 mutations, FBXW7 mutation, and PPP2R1A mutation, as novel synthetic lethal partners. This perspective summarizes, for the first time, the PKMYT1 structure, function, and inhibitors in both the literature and patent applications reported to date. Compounds are described focusing on their design and optimization process, structural features, and biological activity with the aim to promoting further drug discovery efforts targeting PKMYT1 as a potential precision therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsProtein Kinase InhibitorsHumansDrug DiscoveryProtein Serine-Threonine KinasesPrecision MedicineAntineoplastic AgentsClinical Trials as TopicMembrane ProteinsProtein-Tyrosine Kinases

Substanzen

PKMYT1 protein, humanProtein Kinase InhibitorsProtein Serine-Threonine KinasesAntineoplastic AgentsMembrane ProteinsProtein-Tyrosine Kinases

Autor:innen und Institutionen

  • State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, P. R. China.

ORCID-Profile: Hua Xiang, Guoshun Luo

Förderung

  • Natural Science Foundation of Jiangsu Province
  • National Natural Science Foundation of China

Zitieren

APA

Yang, M., Xiang, H., & Luo, G. (2024). Targeting Protein Kinase, Membrane-Associated Tyrosine/Threonine 1 (PKMYT1) for Precision Cancer Therapy: From Discovery to Clinical Trial. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01619

Vancouver

Yang M, Xiang H, Luo G. Targeting Protein Kinase, Membrane-Associated Tyrosine/Threonine 1 (PKMYT1) for Precision Cancer Therapy: From Discovery to Clinical Trial. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01619

BibTeX
@article{Yang2024,
  author = {Yang, Ming and Xiang, Hua and Luo, Guoshun},
  title = {Targeting Protein Kinase, Membrane-Associated Tyrosine/Threonine 1 (PKMYT1) for Precision Cancer Therapy: From Discovery to Clinical Trial},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01619}
}
Kostenlos starten →